Cigna’s health services unit Evernorth announced Wednesday the launch of Pharmacy Forward, an AI-powered specialty pharmacy program backed by $100 million in investment through 2028. The program deploys artificial intelligence to integrate clinical data, generate documentation summaries, and streamline prior authorisation processes. The initial rollout runs through Accredo, Evernorth’s specialty pharmacy operation. Cigna says Pharmacy Forward is expected to reduce clinician documentation time by up to 50%, cut in half the time between prescription receipt and patient medication delivery, and generate approximately $400 million in value by end of 2028. Those are specific, testable claims – which makes this announcement considerably easier to evaluate than the vague AI-adoption pledges that have become standard corporate communication.
The prior authorisation piece is where the clinical impact concentrates. Specialty drugs – biologics, oncology treatments, rare disease therapies – typically require prior authorisation from the insurer before they can be dispensed, a process that can delay patient access by days or weeks while paperwork moves between prescriber, pharmacy, and payer. Cigna says the AI system halves that delay by improving the completeness and accuracy of prior authorisation requests the moment Accredo receives a prescription. YourDailyAnalysis unpacks why this matters specifically in specialty pharmacy: specialty drugs represent a small fraction of total prescriptions but account for more than 50% of total drug spending in the U.S., according to industry estimates. Delays in specialty drug access have measurable clinical consequences, which gives the prior authorisation speed-up real patient-outcome weight beyond administrative efficiency.
The 50% documentation time reduction claim deserves scrutiny. Clinical documentation in pharmacy settings involves structured data entry, unstructured narrative notes, and regulatory compliance records. AI-assisted summarisation can compress the time a clinician spends on the narrative and review functions without necessarily eliminating the underlying clinical judgment that those documents are meant to capture. The team at YourDailyAnalysis draws a sharp line here: Cigna is using AI to handle the mechanical translation of clinical inputs into documentation formats, not to replace the clinical decisions themselves. That is an important distinction – the technology is administrative, not diagnostic.
Zoom out on the competitive landscape. Health insurers including UnitedHealth Group, CVS Health’s Aetna, and Humana have all announced AI programs targeting administrative burden reduction. Prior authorisation specifically has attracted regulatory pressure: the Biden administration finalised rules in 2024 requiring insurers to process electronic prior authorisation requests within 72 hours for urgent cases and seven days for standard ones. AI tools that can reduce preparation time on the pharmacy side of that equation contribute to compliance readiness as much as to operational efficiency. Accredo also operates nearly 40 care facilities, and Cigna says the program will expand staffing and capabilities at those locations alongside the AI deployment.
The $400 million in expected value through 2028 against $100 million in investment implies a 4x return on the programme over roughly two and a half years. That ratio is ambitious but not implausible for a specialty pharmacy operation running at scale, where small improvements in throughput or authorisation success rates translate directly into revenue from drug dispensing and avoided administrative costs. Analysts at Your Daily Analysis measure the $400 million figure against Cigna’s total 2025 revenues of approximately $250 billion – the Pharmacy Forward programme represents less than 0.2% of that base, meaning the financial materiality is modest at the corporate level even if the clinical impact is significant at the patient level.
There is a third scenario that Cigna’s announcement is also telling: the beginning of Evernorth’s bid to extend its AI capabilities beyond Accredo to its broader pharmacy operations. The company said explicitly that it expects to extend Pharmacy Forward’s capabilities to other Evernorth pharmacy operations in coming years. YourDailyAnalysis closes on that extension as the more consequential variable than the initial $100 million commitment. Evernorth’s pharmacy benefit management and speciality drug distribution operations together touch tens of millions of members. A programme that cuts prior authorisation time by half at Accredo scale is a footnote; the same capability applied across Evernorth’s full book of business becomes a genuine structural cost advantage in a sector where administrative friction is one of the primary cost drivers.
